Chronic kidney disease (CKD) is associated with alterations of the gut microbiome, sometimes referred to as dysbiosis. These changes may include reductions in the bacterial species involved in SCFA production and increases in bacterial enzymes involved in the production of uremic toxins (substances that can build up in the body of people with CKD).[1] Because of this, RS has been a supplement of interest given its ability to modulate the microbiome and increase the production of SCFAs in some people. In a 2022 meta-analysis of randomized controlled trials, RS supplementation was found to reduce blood levels of indoxyl sulfate (a uremic toxin associated with worse health outcomes in CKD),[2] phosphorus, interleukin-6, and uric acid in people with CKD undergoing dialysis.[3] While this is promising, it is unclear whether these beneficial effects lead to any meaningful changes in health outcomes, and further research is required.
References
- ^Snelson M, Kellow NJ, Coughlan MTModulation of the Gut Microbiota by Resistant Starch as a Treatment of Chronic Kidney Diseases: Evidence of Efficacy and Mechanistic Insights.Adv Nutr.(2019-Mar-01)
- ^Melamed ML, Plantinga L, Shafi T, Parekh R, Meyer TW, Hostetter TH, Coresh J, Powe NRRetained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators.BMC Nephrol.(2013-Jun-27)
- ^Du X, Wu J, Gao C, Tan Q, Xu YEffects of Resistant Starch on Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.J Diabetes Res.(2022)